Controlling IOP with SLT and latanoprost

Article

Both selective laser trabeculoplasty (SLT) and latanoprost are effective at controlling the level and fluctuation of intraocular pressure (IOP), according to a study published online ahead of print by the British Journal of Ophthalmology.

Both selective laser trabeculoplasty (SLT) and latanoprost are effective at controlling the level and fluctuation of intraocular pressure (IOP), according to a study published online ahead of print by the British Journal of Ophthalmology.

Dr Madhu Mahesh Nagar of Clayton Eye Centre, UK and colleagues treated open-angle glaucoma (OAG) and ocular hypertension (OH) patients (n=40) randomly with either SLT or latanoprost, and measured IOP values at day 3, week 1, month 1 and month 4–6 postoperatively. The team defined IOP control success as a reduction of 20% over preoperative values. The team also measured tension curves before and 4–6 months after treatment, with success defined as a 50% reduction in fluctuation.

Patients treated with SLT experienced a mean IOP decrease of 4.7 mmHg, with a similar level of reduction experienced by latanoprost-treated patients; 75% of SLT-treated patients and 73% of latanoprost-treated patients achieved a successful level of IOP reduction. In terms of reducing fluctuation, latanoprost was the more effective treatment although both methods achieved a statistically significant reduction: latanoprost was successful in 83% of cases and SLT was successful in 50% of cases.

The researchers concluded that both SLT and latanoprost are effective at controlling IOP and reducing fluctuation, both with their own benefits: latanoprost is the more successful at reducing IOP fluctuation whereas SLT is a single interventional treatment, which does not require follow-up.

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.